The retail investor response was rubbish.
IMO, they basically acknowledged they are good at focusing on all things medadvisor and its globalisation (without financial forecasts mind you). However, they are terrible at SH management, and subsequently nothing in their management strategies gives consideration of share price.
We’ll just have to wait for revenue to increase before MDR hits the radar of SIs and retail. How long is anyone’s guess based on vaguety expressed this morning.
Ann: MedAdvisor 2020 Annual Report & Appendix 4E, page-8
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.5¢ |
Change
-0.025(5.00%) |
Mkt cap ! $261.5M | |||
| Open | High | Low | Value | Volume |
| 50.0¢ | 52.0¢ | 47.5¢ | $681.8K | 1.347M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3999 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.5¢ | 1954 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| MDR (ASX) Chart |